Korean biosimilars (biopharmaceutical generics) are strengthening their dominance by consecutively overcoming regulatory barriers in the world’s largest pharmaceutical markets, the United States and Europe. Following their top performance in U.S. FDA (Food and Drug Administration) approvals last year, Korean companies such as Celltrion have also set records for the most approval recommendations by a single company in Europe, further elevating their global market standing.


According to the industry on February 2, a total of 18 biosimilars were approved by the FDA last year, with products from Korean companies such as Celltrion and Samsung Bioepis accounting for 5 of them (about 28%). This placed Korea ahead of India (4 approvals), Germany and China (3 each), and the United States (2), ranking first for the second consecutive year. In terms of cumulative approvals, Korea has reached a total of 19, closely trailing the United States, which has 28. This figure surpasses traditional pharmaceutical powerhouses like Switzerland and Germany, indicating that Korean biosimilars have become mainstream in the U.S. market.

"No.1 in the U.S., Six Approvals in Europe"... K-Biosimilars Sweep the Two Major Markets View original image

Celltrion began last year with the approval of “Aptozema,” a biosimilar of the rheumatoid arthritis treatment Actemra, in January. This was followed in March by approvals for “Stoboclo” and “Osenbelt,” biosimilars of the osteoporosis treatments Prolia and Xgeva, respectively. In the second half of the year, Celltrion also received approvals for “Eydenzelt,” a biosimilar of the ophthalmic drug Eylea, and “Omriclo,” a biosimilar of the asthma treatment Xolair. Notably, “Omriclo” was designated by the FDA as an interchangeable biosimilar, allowing it to be substituted for the original drug at pharmacies without a doctor’s prescription, providing a significant competitive advantage.


Samsung Bioepis also strengthened its portfolio last February by obtaining FDA approvals for “Ospomiv” and “Xbryk,” biosimilars of the bone disease treatments Prolia and Xgeva. With these approvals, Samsung Bioepis has increased its number of approved products in the United States to more than 10, tightening its grip on the local market.


The results in the European market are also remarkable. As of last year, a total of six Korean biosimilars had cleared the hurdles of the European Medicines Agency (EMA) and the European Commission (EC). This ranks Korea second in Europe in terms of the number of approvals, following Germany with eight.


Last year, Celltrion received “approval recommendations” from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for four products at once: Aptozema (rheumatoid arthritis), Eydenzelt (ophthalmic diseases), and Stoboclo and Osenbelt (bone diseases). A CHMP recommendation is effectively equivalent to final approval, and it is unprecedented for a single company to receive recommendations for four products simultaneously. Samsung Bioepis also secured European approvals for two products last year: “Obodence” and “Xbryk.” With these new approvals, Samsung Bioepis now has a total of 11 approved products in Europe, and Celltrion has also completed a portfolio of 11 with the latest four. Together, the two companies now have over 20 products recognized by European regulatory authorities.


The industry believes that these achievements go beyond a mere increase in approval numbers and will serve as a decisive turning point to outpace the pursuit of emerging market pharmaceutical companies such as those from India, whose competition is expected to intensify this year. Celltrion and Samsung Bioepis have secured extensive clinical data and portfolio diversity comparable to multinational pharmaceutical companies. With the addition of these four products, Celltrion has significantly expanded its pipeline beyond autoimmune diseases to include new areas such as ophthalmology and bone diseases, targeting a global market worth a total of 135 trillion won.



An industry insider stated, “In the United States, we are maximizing profitability with ‘interchangeability’ certification, which allows for substitution with original drugs, and in Europe, by leveraging a direct sales system through local subsidiaries. Thanks to overwhelming approval data and the advantages of being first to market, the dominance of Korean biosimilars is expected to remain solid for the foreseeable future.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing